Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 15 January 2026 - 25 January 2026

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
····
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings

AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings

AbbVie shares rose 0.6% to $219.33 Friday after India’s patent office rejected the company’s bid to patent blood-cancer drug venetoclax, raising prospects for generics. The Health Care Select Sector SPDR Fund fell 0.6%. Investors are watching for AbbVie’s Feb. 4 earnings after recent guidance cuts and U.S. pricing deals.
23 January 2026
····
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·····
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie shares rose 0.4% to $214.92 by midday Wednesday after Berenberg raised its price target to $275. Bernstein maintained a Hold rating with a $225 target. Investors are watching for U.S. pharma tariff developments and AbbVie’s Feb. 4 earnings. The stock traded between $211.92 and $218.00 on volume of 5.3 million shares.
21 January 2026
····
AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie shares fell 0.4% to $213.53 in early afternoon trading after phase III results for Epkinly showed a progression-free survival benefit but no statistically significant overall survival in lymphoma patients. The stock moved between $210.00 and $214.23 as investors looked ahead to the Feb. 4 earnings report and 2026 outlook.
20 January 2026
·····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
·······
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie shares fell 1.1% to $214.35 Friday after mixed Phase 3 results for its lymphoma drug epcoritamab, which improved progression-free survival but missed the main goal of overall survival. The stock edged up to $214.66 in after-hours trading. U.S. markets reopen Tuesday after the holiday, with AbbVie’s earnings due Feb. 4.
17 January 2026
·····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
·····
AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie shares fell 2.1% to $217.13 Thursday after executives announced expanded obesity drug plans at the J.P. Morgan Healthcare Conference. The company will develop an amylin-based obesity treatment licensed from Gubra. Investors are watching Friday’s ex-dividend date and the February 4 earnings report for more details on spending and program timing.
15 January 2026
···
1 2 3 4 … 7

Stock Market Today

Corning stock price hits record close — what’s driving GLW and the next big test

Corning stock price hits record close — what’s driving GLW and the next big test

7 February 2026
Corning shares jumped 8.3% to a record $122.16 Friday, gaining 11% over two sessions amid strong demand for AI infrastructure stocks. The move follows a $6 billion optical fiber deal with Meta and upgraded company forecasts. Shares traded as high as $122.56 and rose 0.6% after hours. COO Avery Nelson sold 1,894 shares for tax withholding, retaining 66,050.
PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

7 February 2026
PepsiCo priced €2.5 billion in euro notes across four maturities, with settlement set for Feb. 11, according to an SEC filing. The company plans to use proceeds for general corporate purposes, including repaying commercial paper. Shares closed at $170.49 Friday, up 1.8%. PepsiCo is also cutting U.S. snack prices by up to 15% after consumer pushback.
Go toTop